Supply Chain

Congress voted in favor of a stopgap spending bill Monday that ended the government shutdown and further delayed the enforcement of a 2.3 percent medical device tax, reports STAT.

The FDA approved Baxter International's cardiovascular medication Bivalirudin Monday.

Here are seven drug and medical device companies that made headlines in the past week.

New Jersey's Office of the Attorney General finalized rules limiting drug companies' payments and gifts to healthcare providers, reports Policy and Medicine.

Prescriptions for Tamiflu have seen a more than six-fold increase this flu season compared to last year, according to an analysis from GoodRx.

Paris-based Sanofi will acquire all outstanding shares of Waltham, Mass.-based Bioverativ for approximately $11.6 billion.

Biopharmaceutical giant Celgene will purchase Juno Therapeutics for $9 billion in a move to expand in the increasingly competitive cancer treatment landscape, reports Bloomberg.

In an industry where health systems are facing increasing pressure to do more with less, doctors and nurses are working longer hours with more responsibilities. Meanwhile, hospitals want to reduce costs without sacrificing quality of care. Therefore it’s more important…

The FDA on Thursday released its 2018 Compounding Priorities Plan, which highlights steps the agency will take throughout the year to boost access to compounded drugs while still preserving patient safety.

PTC Therapeutics raised the price of its muscular dystrophy treatment by 9 percent, to more than $65,000 annually for a general dosage, reviving a drug price controversy that arose last year, reports the Wall Street Journal.